+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Bristol-Myers Squibb Co (BMY) - Financial and Strategic SWOT Analysis Review

Bristol-Myers Squibb Co (BMY) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the publisher to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Bristol-Myers Squibb Co (BMS) is a specialty biopharmaceutical company that is engaged in discovery, development, licensing and manufacturing, marketing, distribution and sale of medicines and related medical products to patients with serious diseases. Its primary focus is on cancer, cardiovascular, immunology and fibrotic therapeutic projects. The company offers its products across the world to wholesalers, retail pharmacies, medical professionals, hospitals and government entities. BMS provides its products in the US, Europe, and Japan. The company conducts research to focus on the discovery and development of novel medicines that address serious diseases in areas of significant unmet medical need. BMS is headquartered in New York City, New York, the US.

Bristol-Myers Squibb Co Key Recent Developments

  • Apr 07, 2023: Notice regarding complete settlement of lawsuit on patents relating to anti-PD-1/PD-L1 antibody
  • Mar 29, 2023: Evotec extends collaboration with Bristol Myers Squibb
  • Mar 16, 2023: Evotec announces progress in strategic protein degradation partnership with Bristol Myers Squibb
  • Feb 02, 2023: Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2022

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company

Table of Contents

Section 1 - About the Company
  • Bristol-Myers Squibb Co - Key Facts
  • Bristol-Myers Squibb Co - Key Employees
  • Bristol-Myers Squibb Co - Key Employee Biographies
  • Bristol-Myers Squibb Co - Major Products and Services
  • Bristol-Myers Squibb Co - History
  • Bristol-Myers Squibb Co - Company Statement
  • Bristol-Myers Squibb Co - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
  • Joint Venture
Section 2 - Company Analysis
  • Company Overview
  • Bristol-Myers Squibb Co - Business Description
  • Business Segment: BioPharmaceuticals
  • Overview
  • Performance
  • Geographical Segment: International
  • Performance
  • Geographical Segment: Others
  • Performance
  • Geographical Segment: The US
  • Performance
  • R&D Overview
  • Bristol-Myers Squibb Co - Corporate Strategy
  • Bristol-Myers Squibb Co - SWOT Analysis
  • SWOT Analysis - Overview
  • Bristol-Myers Squibb Co - Strengths
  • Bristol-Myers Squibb Co - Weaknesses
  • Bristol-Myers Squibb Co - Opportunities
  • Bristol-Myers Squibb Co - Threats
  • Bristol-Myers Squibb Co - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • Bristol-Myers Squibb Co, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • Bristol-Myers Squibb Co, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023
  • Bristol-Myers Squibb Co, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • Apr 07, 2023: Notice regarding complete settlement of lawsuit on patents relating to anti-PD-1/PD-L1 antibody
  • Mar 29, 2023: Evotec extends collaboration with Bristol Myers Squibb
  • Mar 16, 2023: Evotec announces progress in strategic protein degradation partnership with Bristol Myers Squibb
  • Feb 02, 2023: Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2022
  • Jan 19, 2023: The Robert A. winn diversity in clinical trials award program established by the Bristol Myers Squibb foundation to expand with amgen’s commitment of $8 million
  • Dec 16, 2022: Evotec achieves further progress in neuroscience collaboration with Bristol Myers Squibb
  • Dec 15, 2022: Bristol Myers Squibb to Report Results for Fourth Quarter 2022 on February 2, 2023
  • Nov 21, 2022: Bristol Myers Squibb data at ASH 2022 highlight innovative therapeutic platforms across a range of blood diseases
  • Oct 27, 2022: Obsidian Therapeutics announces extension of multi-year collaboration agreement with Bristol Myers Squibb
  • Oct 25, 2022: The Robert A. Winn Diversity in Clinical Trials Award Program announces the second group of physicians to be trained in the $114 million program
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About the Publisher
  • Contact the Publisher
  • Disclaimer
List of Tables
  • Bristol-Myers Squibb Co, Key Facts
  • Bristol-Myers Squibb Co, Key Employees
  • Bristol-Myers Squibb Co, Key Employee Biographies
  • Bristol-Myers Squibb Co, Major Products and Services
  • Bristol-Myers Squibb Co, History
  • Bristol-Myers Squibb Co, Subsidiaries
  • Bristol-Myers Squibb Co, Joint Venture
  • Bristol-Myers Squibb Co, Key Competitors
  • Bristol-Myers Squibb Co, Ratios based on current share price
  • Bristol-Myers Squibb Co, Annual Ratios
  • Bristol-Myers Squibb Co, Interim Ratios
  • Bristol-Myers Squibb Co, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • Bristol-Myers Squibb Co, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023
  • Bristol-Myers Squibb Co, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • Bristol-Myers Squibb Co, Performance Chart (2018 - 2022)
  • Bristol-Myers Squibb Co, Ratio Charts
  • Bristol-Myers Squibb Co, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • Bristol-Myers Squibb Co, Pharmaceuticals & Healthcare, Deals by Type, 2017 to YTD 2023

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Omniox Inc
  • Intercept Pharmaceuticals Inc
  • Generex Biotechnology Corp
  • Allergan Ltd
  • Teva Pharmaceutical Industries Ltd
  • Takeda Pharmaceutical Co Ltd
  • Checkpoint Therapeutics Inc
  • Viatris Inc
  • Novartis AG
  • Merck & Co Inc
  • Sanofi
  • GSK plc
  • CTI BioPharma Corp
  • Sandoz Inc
  • Eli Lilly and Co
  • Abbott Laboratories
  • Sangui BioTech International Inc
  • Lescarden Inc
  • Theratechnologies Inc
  • Johnson & Johnson
  • Sangui BioTech International Inc
  • Lescarden Inc
  • Merck & Co Inc
  • CTI BioPharma Corp
  • Novartis AG
  • Omniox Inc
  • Intercept Pharmaceuticals Inc
  • Allergan Ltd
  • Teva Pharmaceutical Industries Ltd
  • Takeda Pharmaceutical Co Ltd
  • Checkpoint Therapeutics Inc
  • Theratechnologies Inc
  • Johnson & Johnson
  • Viatris Inc
  • Sandoz Inc
  • Generex Biotechnology Corp
  • Sanofi
  • GSK plc
  • Eli Lilly and Co
  • Abbott Laboratories